Fig. 1

Amplification and upregulation of MYEOV transcript in NSCLC. a Copy number data for 983 lung cancer samples are shown with genomic locations. The color scale ranges from blue (deletion) through white (neutral; diploid) to red (amplification). False discovery rates (q values; green line is 0.25 cutoff for significance) and scores (log₂ ratio ≥ 0.8) for amplicons are labeled at each genome position; red boxes indicate the top three significant high-level amplifications. b Fold changes of mRNA expression and statistic P-value when comparing NSCLC and noncancerous adjacent tissue on the indicated genes within the amplicon. c Statistical analysis of MYEOV expression in NSCLC and adjacent noncancerous tissue in the TCGA cohort. d MYEOV mRNA expression in 973 NSCLC specimens and 107 normal lung specimens in the TCGA dataset. Horizontal lines represent the means, and each dot represents an individual specimen (median with interquartile range, two-tailed unpaired Student’s t test). e Relationship between the CNVs of MYEOV and its mRNA expression level in the TCGA cohort. Box plot represents lower quartile; median and upper quartile and whiskers represent 95% confidence interval of the mean (one-way ANOVA followed by Bonferroni’s multiple comparison test. **P < 0.01). f MYEOV genomic amplification status confirmed by FISH assay. Red signals indicate the MYEOV, and green signals represent CEP11. g Kaplan–Meier survival analysis of NSCLC patients in the SYSUCC cohort stratified by MYEOV genomic amplification status. h Kaplan–Meier analyses of the correlations between MYEOV expression level and overall survival or recurrence-free survival of NSCLC patients in TCGA dataset and in GSE5843 and GSE50081, respectively. The median expression level was used as the cutoff with the P value of log-rank test presented for each set